Universal DX
Universal DX (UDX) is a biotechnology company specializing in the development of blood-based tests for early cancer detection. By combining high-throughput metabolomics and next-generation sequencing with proprietary bioinformatics and machine learning algorithms, the company aims to transform cancer into a curable disease through early diagnosis. UDX operates at the intersection of oncology, diagnostics, and data science, maintaining a global presence with research and development facilities. Headquartered in Seville, Spain, Universal DX offers a highly technical environment for professionals in software engineering, biostatistics, and laboratory operations. The company is particularly attractive to international talent due to its mission-driven work and the integration of advanced technology in the healthcare sector. Seville serves as a primary hub for their R&D activities, providing a Mediterranean lifestyle alongside cutting-edge scientific innovation.
Company History
Founded in 2012 in Seville, Universal DX has grown into a leading player in the liquid biopsy space. The company has expanded its operations to include offices in the United States and Slovenia to support its global clinical trials and commercialization efforts.
For International Professionals
- Focuses on early cancer detection using liquid biopsy and AI-driven diagnostics.
- Primary R&D and laboratory facilities are located in Seville, a growing tech hub in southern Spain.
- Multidisciplinary team environment including biologists, data scientists, and software engineers.
- English is frequently used as a working language for technical and scientific documentation.
- Offers opportunities for international professionals to enter the specialized Spanish MedTech ecosystem.